1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63A4F2A7DEE5032DA00258568003C5AC0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-oversight-management-investigator-initiated-trials-structure-activities-responsibilities?opendocument
18
19opendocument
2018.206.194.134
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Clinical Trials

Best Practices in the Management of Investigator Initiated Trials: Structure, Activities and Responsibilities

ID: 5614


Features:

7 Info Graphics

23 Data Graphics

300+ Metrics

10 Narratives


Pages/Slides: 41


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in the Management of Investigator Initiated Trials: Structure, Activities and Responsibilities”

STUDY OVERVIEW

As the number of investigator initiated trial (IIT) submissions continues to rise, it is important for biopharmaceutical companies to properly vet each proposal and approve the ones that demonstrate scientific merit and align with corporate objectives.

Best Practices, LLC undertook this benchmarking research to provide a detailed roadmap for improving IIT management at bio-pharmaceutical companies, capturing critical metrics and insights on IIT management team structure, activities, responsibilities, leadership, SOPs, proposal evaluation and review process.

This study serves as a reference point for pharma leaders who oversee or work in investigator-initiated trials so that they can compare the critical aspects of their IIT program with those of industry peers.



KEY TOPICS

  • IIT Submission Review and Systems
  • Functional Involvement
  • Important Criteria for IIT Evaluation
  • Key Reasons for Rejecting IIT Proposals

KEY METRICS
  • What type of IIT studies does your organization support?
  • What is the involvement of various functions during proposal collection and initial screening of the IIT process?
  • What is the level of position of the IIT operational team lead?
  • Do you have written SOPs for IIT processes?
  • How frequently does the IIT review committee meet?
  • What role do MSLs play in IIT management?
  • What are the most important criteria when evaluating an IIT proposal?
  • How do you review concept proposals on a rolling basis or within a submission window?

SAMPLE KEY FINDINGS
  • Strategic fit and scientific merit most often determine IIT approval; high costs and strategic misalignment lead to IIT denials
    • The most used criteria for evaluating new IIT proposals were “strategic fit” and “scientific value.”
    • Some companies also evaluate based on “clinical feasibility” and “potential impact.” IIT denials occur most often because of strategic misalignment and high costs.
METHODOLOGY

Best Practices, LLC engaged 46 leaders from 34 bio-pharmaceutical and medical device companies in this research through a benchmarking survey. Nearly three-fourths of the respondents serve at the director level or above.


Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Allergan; Arena Pharmaceuticals; Bayer; Beckman Coulter; Becton Dickinson; Biofrontera; Bioventus; Blue Earth Diagnostics; Cipla; Daiichi Sankyo; Edwards Lifesciences; Eisai; EMD Serono; Fidia; Gedeon Richter ; Grifols; Guerbet; Ipsen; Jazz Pharmaceuticals; Julphar; Karyopharm Therapeutics; Lundbeck; Merck; Merz Pharma; Novartis; Sage Therapeutics; Sandoz; Sanofi; Santen; Seqirus; Solidfarma; Takeda Pharmaceuticals; Terumo Corporation

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.